Clinical effect of edaravone combined with urokinase intravenous thrombolytic therapy on cerebral infarction and its influence on BNP and cystatin C levels
Objective To investigate the clinical efficacy of edaravone combined with urokinase intravenous thrombolytic therapy in the treatment of cerebral infarction and the effect on the levels of BNP and cystatin C.Methods 130 patients with cerebral infarction enrolled from May 2020 to April 2023 were selected and divided into the control group and the study group(n=65)according to random number method.The control group received intravenous urokinase thrombolytic therapy,and the study group received intravenous urokinase thrombolytic therapy combined with edaravone.The clinical efficacy,neurological function,BNP level,cystatin C level and the occurrence of adverse reactions were evaluated in the two groups.Results The total effective rate of the study group was higher than that of the control group(P＜0.05).The NIHSS score of the study group at 7 and 14 days after treatment was lower than that of the control group(P＜0.05).The study group of BNP and CysC levels in 1 d,2 d and 7 d were lower than those in the control group(P＜0.05).There were 5 cases of adverse reactions in the study group and 3 cases in the control group,and there was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Edaravone combined with urokinase can improve nerve function,BNP and cystatin C level in patients with cerebral infarction with high safety.
EdaravoneIntravenous thrombolytic therapy with urokinaseCerebral infarctionClinical effectBNPCystatin C
NETL
NSTL
万方数据
